ISTO Technologies, Inc.is both a regenerative medicine and orthopedics company developing innovative cartilage and bone regeneration products for spinal therapy, sports medicine and trauma. ISTO is currently focused on the development of cell-based cartilage platform technology that can be applied to repair and regenerate damaged cartilage in the knee and spinal disc.
Aridis Pharmaceuticals is a private biotechnology company focusing on improved alternatives to traditional antibiotics for the treatment of pneumonia and Cystic Fibrosis in addition to a few other conditions.
Cognoptix and its technology have the ability to overhaul commonly accepted Alzheimer’s Disease diagnostic practices, providing a tool to diagnose the disease at an early stage, thereby increasing the efficacy of current therapies.
GreeneStone Healthcare Corp. (OTCBB: GRST) operates medical clinics in Ontario, Canada. GreeneStone adds capacity to an increasingly stretched provincial healthcare system, and provides private alternatives to publicly under-serviced niches. Greenestone President and CEO Shawn Leon spoke with OneMedRadio about market opportunity for clinics in the unique Canadian healthcare system, and evolving valuation drivers in this space.
Metabiomics is developing a noninvasive screening test for colon polyps in colorectal cancer based on human microbiome markers. In an interview with OneMedRadio, Gregory Kuehn, Vice President of Business Development at Metabiomics, explained that the preliminary data showed “sensitivity in excess of 97%” and specificity “as high as 93%.” Metabiomics will present at the upcoming OneMedForumNY 2013 on June 27th.
OneMedRadio spoke with Cynthia Nolte, Director, Medical Device Regulatory Services for Aptiv Solutions, about the state of mobile health/health information technology regulatory, clinical trial design for mobile health technology, and what we can expect from future guidelines. The conclusions about regulating a rapidly evolving space — and the case studies that have pioneered this process — are intriguing, and indeed promising.
Charlottesville, VA-based Functional Neuromodulation is conducting an advanced trial of the application of Deep Brain Stimulation (DBS) therapy as a supplement for current Alzheimer’s Disease treatments. OneMedRadio’s Matt Margolis spoke with Dan O’Connell, co-founder and CEO of Functional Neuromodulation, about the science behind applying Deep Brain Stimulation to Alzheimer’s Disease, its current clinical trial, the lack of venture capital for Alzheimer’s research, and the regulatory obstacles that Functional Neuromodulation will face in the future.
The effectiveness of Genentech and Roche’s (RHHBY.OB) glioblastoma multiforme (GBM) treatment, Avastin, has recently been challenged raising concerns from physicians and patients alike that a huge void in patient care can develop if the FDA decides to revoke Avastin’s approval for treating GBM.
Or, How I Learned to Stop Worrying and Love Computational Biology.
On May 29th, 2013, GlaxoSmithKline (GSK) announced the acquisition of Okairos in an all-cash deal worth $325 million US. The Okairos acquisition helps complement the pharma giant’s existing vaccine technology and expertise and will enable GSK to continue its work developing the next generation of vaccines.
Copyright © 2024 | WordPress Theme by MH Themes